SEC Form 4 · accession 0001385508-18-000086

OPIANT PHARMACEUTICALS, INC. · OPNT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director · 10% Owner

Period of report

Oct 2, 2018

Accepted (ET)

Oct 4, 2018 · 4:47 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001385508

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Oct 2, 2018	M	29,297	$7.25	A	37,772	D
Common Stock	Oct 2, 2018	S	10,144	$17.51	D	27,628	D
Common Stock^F3	Oct 3, 2018	S	4,300	$19.23	D	23,328	D
Common Stock	Oct 4, 2018	S	4,006	$18.43	D	19,322	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option^F4	$7.25	Oct 2, 2018	M	50,000	D	Oct 27, 2015	Oct 26, 2025	Common Stock	29,297	450,000	D

F1The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F2The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F3This transaction was executed in multiple trades at prices ranging from $19.00 to $19.75. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4Pursuant to the Stock Option Agreement, the number of shares issued on a cashless basis is determined by the following formula: Number of shares = (number of options times (prior day closing stock price less exercise price)) divided by the prior day closing stock price.